Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Accounts Payables (2021 - 2025)

Historic Accounts Payables for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $215.0 million.

  • Indivior Pharmaceuticals' Accounts Payables rose 12638.04% to $215.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.0 million, marking a year-over-year increase of 12638.04%. This contributed to the annual value of $216.0 million for FY2024, which is 1076.92% up from last year.
  • Per Indivior Pharmaceuticals' latest filing, its Accounts Payables stood at $215.0 million for Q3 2025, which was up 12638.04% from $196.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Accounts Payables ranged from a high of $720.0 million in Q4 2021 and a low of -$815.0 million during Q3 2024
  • In the last 5 years, Indivior Pharmaceuticals' Accounts Payables had a median value of $189.0 million in 2023 and averaged -$119.9 million.
  • Per our database at Business Quant, Indivior Pharmaceuticals' Accounts Payables plummeted by 6839.55% in 2023 and then surged by 12638.04% in 2025.
  • Over the past 5 years, Indivior Pharmaceuticals' Accounts Payables (Quarter) stood at $720.0 million in 2021, then fell by 14.31% to $617.0 million in 2022, then crashed by 68.4% to $195.0 million in 2023, then rose by 10.77% to $216.0 million in 2024, then fell by 0.46% to $215.0 million in 2025.
  • Its Accounts Payables was $215.0 million in Q3 2025, compared to $196.0 million in Q2 2025 and $183.0 million in Q1 2025.